<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02676544</url>
  </required_header>
  <id_info>
    <org_study_id>803676</org_study_id>
    <nct_id>NCT02676544</nct_id>
  </id_info>
  <brief_title>Prostate Embolization for Massive Benign Prostatic Hypertrophy (BPH)</brief_title>
  <official_title>Prostate Embolization for Massive Benign Prostatic Hypertrophy (BPH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rhode Island Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rhode Island Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, open label single center feasibility study to demonstrate basic safety&#xD;
      and effectiveness of prostate artery embolization for the treatment of symptomatic benign&#xD;
      prostatic Hyperplasia (BPH) in a small series of patients with large (≥90 grams) glands.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, open labeled, non-randomized, single center feasibility study to&#xD;
      evaluate the technical and clinical success of prostatic artery embolization utilizing&#xD;
      Embosphere microspheres.&#xD;
&#xD;
      At initial consultation patients will be screened to assess the severity of lower urinary&#xD;
      tract symptoms (LUTS) related to BPH utilizing the international prostate symptom score&#xD;
      (IPSS). After determining eligibility, pre-procedure baseline evaluation will be completed. A&#xD;
      baseline prostate ultrasound (TRUS) or MRI will be required to assess prostate mass, and&#xD;
      baseline prostate-specific antigen will be measured to help exclude carcinoma and also to&#xD;
      follow response to therapy. Patients with suspected malignancy of the prostate will not be&#xD;
      enrolled without a negative biopsy finding. Pre- procedure urodynamic studies will be&#xD;
      required to assess additional objective measurements and to exclude other causes of LUTS.&#xD;
      Cystoscopy will be performed prior to any intervention to help exclude bladder malignancy.&#xD;
&#xD;
      If the patient qualifies by the level of symptoms (IPSS score ≥12), prostate size ≥ 90 grams&#xD;
      and max urinary flow rate (Qmax) ≤ 12, the patient will be asked to consider enrolling in the&#xD;
      study. A study investigator will review the proposed treatment and baseline/follow-up&#xD;
      schedule. If the patient agrees to participate in the study, baseline data will be collected&#xD;
      on a case report form and an appointment will be made for prostate artery embolization in the&#xD;
      interventional radiology department.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Device approved for this use&#xD;
  </why_stopped>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">June 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Improvement in Lower Urinary Tract Symptoms (LUTS)</measure>
    <time_frame>24 months</time_frame>
    <description>Questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Safety and Tolerability as assess by CTCAE 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in peak urinary flow (Qmax)</measure>
    <time_frame>24 months</time_frame>
    <description>Urodynamics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in prostate size</measure>
    <time_frame>24 months</time_frame>
    <description>Imaging (MRI or Transrectal ultrasound)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum PSA from baseline</measure>
    <time_frame>24 months</time_frame>
    <description>Blood test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erectile and sexual function questionnaire</measure>
    <time_frame>24 months</time_frame>
    <description>Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>12 months</time_frame>
    <description>Pain Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post void residual bladder volume (PVR)</measure>
    <time_frame>24 months</time_frame>
    <description>Imaging (ultrasound)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Procedural time in minutes</measure>
    <time_frame>1 day</time_frame>
    <description>Total PAE time for informational purposes</description>
  </other_outcome>
  <other_outcome>
    <measure>Total fluoroscopy time in minutes</measure>
    <time_frame>1 day</time_frame>
    <description>Total procedural fluoroscopy time in minutes for informational purposes</description>
  </other_outcome>
  <other_outcome>
    <measure>Size of catheter used for embolization</measure>
    <time_frame>1 day</time_frame>
    <description>Microcatheter size for informational purposes</description>
  </other_outcome>
  <other_outcome>
    <measure>Volume of contrast used in mL</measure>
    <time_frame>1 day</time_frame>
    <description>For informational purposes</description>
  </other_outcome>
  <other_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>1 day</time_frame>
    <description>Expected to be less than 1 day</description>
  </other_outcome>
  <other_outcome>
    <measure>Volume of embolic material used in mL</measure>
    <time_frame>1 day</time_frame>
    <description>Total volume per prostatic artery utilized to achieve stasis</description>
  </other_outcome>
  <other_outcome>
    <measure>Total fluoroscopy dose mGy</measure>
    <time_frame>1 day</time_frame>
    <description>Measured in mGy for informational purposes</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Benign Prostatic Hypertrophy</condition>
  <condition>Lower Urinary Tract Symptoms</condition>
  <arm_group>
    <arm_group_label>Embosphere microspheres</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Embospheres are calibrated microspheres which will be percutaneously delivered intra-arterially via a microcatheter under fluoroscopic guidance to occlude the prostatic arteries.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Embosphere microspheres</intervention_name>
    <description>This is a clinical trial assessing the feasibly and safety of prostate artery embolization (PAE) for benign prostatic hypertrophy (BPH) resulting in severe lower urinary tract symptoms (LUTS) in patients with gland size ≥90 grams who are TURP ineligible or non-operative candidates with Embosphere microspheres.</description>
    <arm_group_label>Embosphere microspheres</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients selected for this study must meet all of the following criteria:&#xD;
&#xD;
               -  Age ≥ 50 years&#xD;
&#xD;
               -  Lower urinary tract symptoms secondary to BPH as defined by:&#xD;
&#xD;
               -  IPSS Symptom Index ≥ 12&#xD;
&#xD;
               -  Maximum Uroflow rate (Qmax) of ≤ 12cc per sec&#xD;
&#xD;
               -  Prostate of ≥ 90 gm as determined by MRI or transrectal ultrasound of the&#xD;
                  prostate (TRUS)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients meeting any of the following criteria will be excluded from the study.&#xD;
&#xD;
               -  Age less than 50 years&#xD;
&#xD;
               -  Prostate cancer&#xD;
&#xD;
               -  Bladder cancer&#xD;
&#xD;
               -  Severe, life-threatening allergy to iodinated contrast&#xD;
&#xD;
               -  Bilateral internal iliac artery occlusion&#xD;
&#xD;
               -  Causes of obstruction other than BPH such as stricture disease&#xD;
&#xD;
               -  Neurogenic bladder or other causes of bladder atonia&#xD;
&#xD;
               -  Post void residual greater than 250 cc&#xD;
&#xD;
               -  Any contraindication to embolization, including&#xD;
&#xD;
               -  Patients intolerant to occlusion procedures&#xD;
&#xD;
               -  Vascular anatomy or blood flow that precludes catheter placement or embolic agent&#xD;
                  injection&#xD;
&#xD;
               -  Presence or likely onset of vasospasm&#xD;
&#xD;
               -  Presence or likely onset of hemorrhage&#xD;
&#xD;
               -  Presence of severe atheromatous disease&#xD;
&#xD;
               -  Presence of feeding arteries smaller than distal branches from which they emerge&#xD;
&#xD;
               -  Presence of collateral vessel pathways potentially endangering normal territories&#xD;
                  during embolization&#xD;
&#xD;
               -  History of any illness or surgery that might confound the results of the study,&#xD;
                  which produces symptoms that might be confused with those of the disease process&#xD;
                  under consideration, or which poses additional risk to the patient.&#xD;
&#xD;
               -  Previous prostate surgery, balloon dilatation, stent implantation, laser&#xD;
                  prostatectomy, hyperthermia, or any other invasive treatment to the prostate&#xD;
&#xD;
               -  Confirmed or suspected bladder cancer&#xD;
&#xD;
               -  Previous rectal surgery (other than hemorrhoidectomy) or history of rectal&#xD;
                  disease&#xD;
&#xD;
               -  Previous pelvic irradiation or radical pelvic surgery&#xD;
&#xD;
               -  Recent (within 3 months) cystolithiasis&#xD;
&#xD;
               -  History or presence of urethral strictures, bladder neck contracture, potentially&#xD;
                  confounding bladder pathology, or (within 5 years) prostatitis&#xD;
&#xD;
               -  Active urinary tract infection&#xD;
&#xD;
               -  Concomitant medications:&#xD;
&#xD;
                  (i) Use of anti histaminics, anti convulsants, and antispasmodics within 1 week&#xD;
                  of treatment unless there is documented evidence that the patient has been on the&#xD;
                  same drug dose for at least 6 months with a stable voiding pattern (the drug dose&#xD;
                  should not be altered or discontinued for entrance into or throughout the study)&#xD;
                  (ii) Use of alpha blockers, anti-cholinergics, androgens, and&#xD;
                  gonadotropins-releasing hormonal analogs within 2 months of treatment (iii) Use&#xD;
                  of 5 alpha reductase inhibitors within 6 months of treatment&#xD;
&#xD;
               -  Compromised renal function (i.e. serum creatinine level greater than 1.8 mg/dl,&#xD;
                  or upper-tract disease)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 17, 2016</study_first_submitted>
  <study_first_submitted_qc>February 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2016</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rhode Island Hospital</investigator_affiliation>
    <investigator_full_name>Albert Scappaticci</investigator_full_name>
    <investigator_title>PhD, MD</investigator_title>
  </responsible_party>
  <keyword>Prostate Artery Embolization (PAE)</keyword>
  <keyword>Benign Prostatic Hyperplasia (BPH)</keyword>
  <keyword>Lower Urinary Tract Symptoms (LUTS)</keyword>
  <keyword>PAE</keyword>
  <keyword>BPH</keyword>
  <keyword>LUTS</keyword>
  <keyword>Prostate Artery Embolization</keyword>
  <keyword>Embospheres</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

